Diarrhea News and Research

Latest Diarrhea News and Research

FDA approves Berinert for the treatment of hereditary angioedema

The U.S. Food and Drug Administration today approved Berinert, the first treatment for acute abdominal attacks and facial swelling associated with a rare and potentially life-threatening genetic disease called hereditary angioedema (HAE).

12 Oct 2009

AP examines H1N1 surveillance by U.S., WHO

The Associated Press examines how the decision by U.S. health officials to stop counting new cases of H1N1 (swine flu) in July has complicated the government's ability to assess groups particularly hard hit by the virus.

9 Oct 2009

Additional Zenvia Phase III results in multiple sclerosis announced by AVANIR

AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) today announced additional detailed results from the confirmatory double-blind Phase III STAR trial evaluating two doses of the investigational drug Zenvia™ (dextromethorphan/quinidine) compared to placebo in the treatment of pseudobulbar affect (PBA) among patients with underlying multiple sclerosis (MS) or amyotrophic lateral sclerosis (ALS). Over the course of the 12-week study in the MS patient subset, Zenvia 30/10 mg met the primary efficacy endpoint by reducing PBA episode rates by an incremental 11.9% beyond placebo

9 Oct 2009

FDA Advisory Committee approves use of Selzentry tablets in combination with HIV therapy

Pfizer Inc. announced today that the U.S. Food and Drug Administration’s (FDA) Antiviral Drugs Advisory Committee voted (10 to 4) to recommend the approval of Selzentry (maraviroc) tablets for use in treatment-naïve adult patients with CCR5-tropic HIV-1 virus as part of combination therapy.

9 Oct 2009

FDA files complaint against Rel's Foods for selling adulterated food products

The U.S. Department of Justice, on behalf of the U.S. Food and Drug Administration, has filed a complaint for permanent injunction against Rel's Foods Inc. (Rel's), of Oakland, Calif., seeking to stop the company from manufacturing, producing, and selling adulterated food products.

9 Oct 2009

Countries make little progress in implementing life-saving techniques to treat children with diarrhea

Despite evidence that low-cost diarrhea treatments such as lower osmolarity oral rehydration salts (ORS) and zinc supplements could drastically reduce the number of deaths among children, little progress has been made in implementing these life-saving techniques, according to researchers at the Johns Hopkins Bloomberg School of Public Health.

9 Oct 2009

Biocodex secures consumer distribution with CVS stores nationwide for its Florastor

As part of its continued expansion throughout the U.S. retail market, Biocodex, Inc., the U.S. arm of the French manufacturer of Florastor® and Florastor® Kids, has secured consumer distribution with CVS stores nationwide beginning this month. Florastor will be placed on-shelf in the stomach/digestives aisle, while Florastor Kids will be available upon request “behind the counter.”

8 Oct 2009

Napo Pharmaceuticals hosts educational panel to address global health and environment

Napo Pharmaceuticals, Inc. (Napo) recently hosted an educational panel to address the impact of the lack of access to clean water and enteric disease on global health, the environment, and human rights.

8 Oct 2009

U.N. appeals for $74m to provide emergency assistance in the Philippines; health-effects of other natural disasters

The U.N. on Tuesday launched an appeal for $74 million "to provide emergency assistance to hundreds of thousands of victims of two catastrophic typhoons that have struck the Philippines in less than two weeks," VOA News reports (Schlein, 10/6).

8 Oct 2009

Gen-Probe to acquire Prodesse for $60 million in cash

Gen-Probe Incorporated announced today that it has signed a definitive agreement to acquire Prodesse, Inc., a privately held leader in molecular testing for influenza and other infectious diseases, for approximately $60 million in cash. Gen-Probe's purchase price could increase to up to $85 million if Prodesse achieves certain financial and regulatory milestones in 2010 and 2011.

7 Oct 2009

Merz publishes Phase III study results assessing the impact of NT 201 on muscle tone

Data results published this month in Clinical Neuropharmacology, revealed that Merz Pharmaceuticals' NT 201 (botulinum toxin type A free from complexing proteins), also known by the brand name Xeomin in Europe and Canada, was statistically significantly more efficacious than placebo for the treatment of patients with post-stroke upper limb spasticity.

7 Oct 2009

Salix Pharmaceuticals granted rights to use Lupin's bioadhesive drug delivery technology

Pharma Major, Lupin Ltd today announced that it has granted Salix Pharmaceuticals, Ltd. the exclusive rights for the United States to its bioadhesive drug delivery technology for use with Rifaximin.

6 Oct 2009

$40B needed to 'dramatically' reduce millions of child deaths annually, report says

Two million infants die within 24 hours of birth each year and almost nine million children died before the age of 5 in 2008, according to a report by Save the Children, which says it would take $40 billion annually to "dramatically" cut these numbers, Agence France-Presse reports (Mohiuddin, 10/5).

5 Oct 2009

Baxter launches HYLENEX recombinant for pediatric rehydration at the 2009 ACEP

Baxter International Inc. today announced the commercial launch of HYLENEX recombinant (hyaluronidase human injection) for use in pediatric rehydration at the 2009 American College of Emergency Physicians (ACEP) scientific assembly (Boston). HYLENEX, an enzyme, allows fluids to be administered under the skin (subcutaneously) rather than through a vein.

From Baxter International Inc. 5 Oct 2009

Lupin grants Salix exclusive rights to its bioadhesive drug delivery technology for use with rifaximin

Salix Pharmaceuticals, Ltd. today announced that as of September 30, 2009 Lupin Ltd. granted Salix the exclusive right in the United States to its bioadhesive drug delivery technology for use with rifaximin. Salix and Lupin have entered into a development, commercialization and license agreement under which the two companies will collaborate in the development and commercialization of a product incorporating rifaximin and utilizing Lupin’s proprietary technology.

5 Oct 2009

Former President Clinton awards certification for new clean water system

The first chlorination system designed for cities in poor countries is now operating in Port-au-Prince, Haiti, announced Andrew Weiss at the Clinton Global Initiative (CGI) meeting in New York last week. "It's a great success," said Weiss.

5 Oct 2009

Bradycardia more likely in patients taking cholinesterase inhibitors

People taking one of several drugs commonly prescribed to treat Alzheimer's disease are more likely to be hospitalized for a potentially serious condition called bradycardia than patients not taking these medications.

3 Oct 2009

Researchers screen decades-old frozen infant stool samples to detect norovirus

A search through decades-old frozen infant stool samples has yielded rich dividends for scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

3 Oct 2009

Mayo study reveals infliximab reduces the need for colectomy

A new study led by Mayo Clinic researchers has found that ulcerative colitis patients had a 41 percent reduction in colectomy after a year when treated with infliximab, according to a study published in the October 2009 issue of Gastroenterology.

1 Oct 2009

Health Canada approves VIBATIV for treating complicated skin and skin structure infections

Astellas Pharma Canada, Inc. announced today that Health Canada has approved VIBATIV(TM) (telavancin) for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including Staphylococcus aureus, both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains.

1 Oct 2009

Diarrhea News and Research

Latest Diarrhea News and Research

FDA approves Berinert for the treatment of hereditary angioedema

AP examines H1N1 surveillance by U.S., WHO

Additional Zenvia Phase III results in multiple sclerosis announced by AVANIR

FDA Advisory Committee approves use of Selzentry tablets in combination with HIV therapy

FDA files complaint against Rel's Foods for selling adulterated food products

Countries make little progress in implementing life-saving techniques to treat children with diarrhea

Biocodex secures consumer distribution with CVS stores nationwide for its Florastor

Napo Pharmaceuticals hosts educational panel to address global health and environment

U.N. appeals for $74m to provide emergency assistance in the Philippines; health-effects of other natural disasters

Gen-Probe to acquire Prodesse for $60 million in cash

Merz publishes Phase III study results assessing the impact of NT 201 on muscle tone

Salix Pharmaceuticals granted rights to use Lupin's bioadhesive drug delivery technology

$40B needed to 'dramatically' reduce millions of child deaths annually, report says

Baxter launches HYLENEX recombinant for pediatric rehydration at the 2009 ACEP

Lupin grants Salix exclusive rights to its bioadhesive drug delivery technology for use with rifaximin

Former President Clinton awards certification for new clean water system

Bradycardia more likely in patients taking cholinesterase inhibitors

Researchers screen decades-old frozen infant stool samples to detect norovirus

Mayo study reveals infliximab reduces the need for colectomy

Health Canada approves VIBATIV for treating complicated skin and skin structure infections

Pharmaceutical Manufacturing - Industry Focus eBook eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Diarrhea News and Research

Latest Diarrhea News and Research

Pharmaceutical Manufacturing - Industry Focus eBook eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in